 | Up a level |
Journal Article
Michel, Christian, Burchert, Andreas, Hochhaus, Andreas, Saussele, Susanne, Neubauer, Andreas, Lauseker, Michael, Krause, Stefan W., Kolb, Hans-Jochem, Hossfeld, Dieter Kurt, Nerl, Christoph, Baerlocher, Gabriela M., Heim, Dominik, Bruemmendorf, Tim H., Fabarius, Alice, Haferlach, Claudia, Schlegelberger, Brigitte, Balleisen, Leopold, Goebeler, Maria-Elisabeth, Haenel, Mathias, Ho, Anthony, Dengler, Jolanta, Falge, Christiane, Moehle, Robert, Kremers, Stephan, Kneba, Michael, Stegelmann, Frank, Koehne, Claus-Henning, Lindemann, Hans-Walter, Waller, Cornelius F., Spiekermann, Karsten, Berdel, Wolfgang E., Mueller, Lothar, Edinger, Matthias, Mayer, Jiri, Beelen, Dietrich W., Bentz, Martin, Link, Hartmut, Hertenstein, Bernd, Fuchs, Roland, Wernli, Martin, Schlegel, Frank, Schlag, Rudolf, de Wit, Maike, Truemper, Lorenz, Hebart, Holger, Hahn, Markus, Thomalla, Joerg, Scheid, Christof, Schafhausen, Philippe, Verbeek, Walter, Eckart, Michael J., Gassmann, Winfried, Schenk, Michael, Brossart, Peter, Wuendisch, Thomas, Geer, Thomas, Bildat, Stephan, Schaefer, Erhardt, Hasford, Joerg, Hehlmann, Ruediger and Pfirrmann, Markus (2019). Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. Haematologica, 104 (5). S. 955 - 963. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Schneeweiss, Andreas, Moebus, Volker, Tesch, Hans, Hanusch, Claus, Denkert, Carsten, Luebbe, Kristina, Huober, Jens, Klare, Peter, Kuemmel, Sherko, Untch, Michael, Kast, Karin, Jackisch, Christian, Thomalla, Joerg, Ingold-Heppner, Barbara, Blohmer, Jens-Uwe, Rezai, Mahdi, Frank, Matthias, Engels, Knut, Rhiem, Kerstin, Fasching, Peter Andreas, Nekljudova, Valentina, von Minckwitz, Gunter and Loibl, Sibylle (2019). Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. Eur. J. Cancer, 106. S. 181 - 193. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852